Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492969 | 1.00 | OGA (0.34) | OGAPRMT5WDR77DYRK1AALDH1A1 | |
| SCHEMBL30492966 | 1.00 | OGA (0.34) | OGAPRMT5WDR77DYRK1AALDH1A1 | |
| SCHEMBL24517470 | 0.79 | DYRK1A (0.42) | OGADYRK1AALDH1A1CYP1A2ACHE | |
| SCHEMBL10199960 | 0.76 | HTR2A (0.37) | ALDH1A1 | |
| SCHEMBL15435738 | 0.75 | OGA (0.39) | OGADYRK1AALDH1A1CYP1A2ACHE | |
| Hydrochloric Acid SCHEMBL2112542 | 0.74 | HTR2A (0.36) | — | |
| SCHEMBL30601503 | 0.73 | GRM5 (0.52) | PRMT5WDR77ALDH1A1 | |
| SCHEMBL22439215 | 0.73 | GRM5 (0.52) | PRMT5WDR77ALDH1A1 | |
| SCHEMBL19844887 | 0.72 | ITGB2 (0.37) | ALDH1A1 | |
| SCHEMBL30729979 | 0.72 | PTGS1 (0.34) | OGADYRK1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2023208143-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| EP-3810275-B1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3810275-B1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-112312969-B | 2, 3-dihydrofuro [2,3-b ] pyridine compounds | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11214576-B2 | 2,3-dihydrofuro[2,3-b]pyridine compounds | ELI LILLY AND COMPANY (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214576-B2 | 2,3-dihydrofuro[2,3-b]pyridine compounds | ELI LILLY AND COMPANY (US) | 2022-01-04 | — | — | US | disclosed |
| WO-2021110656-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021094312-A1 | PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3810275-A1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | Eli Lilly and Company (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210070766-A1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-03-11 | — | — | US | disclosed |
| US-20210070766-A1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-03-11 | — | — | US | disclosed |
| CN-112312969-A | 2, 3-dihydrofuro [2,3-b ] pyridine compound | 伊莱利利公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | OGA 983/4885PRMT5 2362/4885WDR77 3194/4885 |
| US-11214576-B2 | 2,3-dihydrofuro[2,3-b]pyridine compounds | PSEN2, PSEN1, PARK7 | OGA 4074/4885PRMT5 446/4885WDR77 1477/4885 |
| US-20210070766-A1 | 2,3-DIHYDROFURO[2,3-B]PYRIDINE COMPOUNDS | PSEN2, PSEN1, PARK7 | OGA 4074/4885PRMT5 446/4885WDR77 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.